HC Wainwright Reiterates “Buy” Rating for Can-Fite BioPharma (NYSEAMERICAN:CANF)

HC Wainwright restated their buy rating on shares of Can-Fite BioPharma (NYSEAMERICAN:CANF – Get Rating) in a report issued on Monday, Benzinga reports. HC Wainwright currently has a $34.00 price objective on the biotechnology company’s stock.

Separately, Dawson James lowered Can-Fite BioPharma from a buy rating to a neutral rating in a research report on Tuesday, January 3rd.

Can-Fite BioPharma Stock Performance

NYSEAMERICAN:CANF opened at $2.52 on Monday. Can-Fite BioPharma has a 12-month low of $2.41 and a 12-month high of $12.90. The firm has a market capitalization of $7.61 million, a PE ratio of -5.60 and a beta of 1.55.

Institutional Trading of Can-Fite BioPharma

A hedge fund recently bought a new stake in Can-Fite BioPharma stock. Virtu Financial LLC bought a new stake in Can-Fite BioPharma Ltd. (NYSEAMERICAN:CANF – Get Rating) during the second quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The fund bought 56,322 shares of the biotechnology company’s stock, valued at approximately $52,000. Virtu Financial LLC owned about 0.21% of Can-Fite BioPharma as of its most recent filing with the Securities and Exchange Commission (SEC). 1.85% of the stock is currently owned by hedge funds and other institutional investors.

About Can-Fite BioPharma

(Get Rating)

Can-Fite BioPharma Ltd. is a biopharmaceutical company, which engages in the development of drugs for the treatment of cancer, liver and inflammatory diseases and erectile dysfunction. Its product pipeline include Piclidenoson, Namodenoson, and CF602. The company was founded by Pnina Fishman and Ilan Cohn on September 11, 1994 and is headquartered in Petach-Tikva, Israel.